Company: STAA
Filing Date: 2025-08-29
Form Type: PREM14A
Source: 0001193125-25-192889
Chunk: 81

Company: STAAR SURGICAL CO
Filing Date: 2025-08-29
Form: PREM14A
Chunk 81
---
 and “The Merger                                                   
 Agreement—Termination Fees”;                                                                                                                                                                                                                         |

| • |     | the fact that the Company Termination Fee was viewed by the Board as relatively favorable to the Company under           
 the circumstances and not likely to preclude or unduly deter another party from making a competing acquisition proposal; |

| • |     | the Board’s right, under the Merger Agreement, to withdraw, qualify or modify its recommendation that STAAR                
 stockholders vote to adopt the Merger Agreement under certain circumstances, subject to the terms of the Merger Agreement; |

| • |     | the fact that the Merger is not subject to a financing condition, and that Alcon has represented that it has and 
 will have available funds sufficient to pay the Merger Consideration;                                            |

| • |     | Alcon’s obligations under the Merger Agreement to use reasonable best efforts to take all actions necessary                                                                                                                                   
 to consummate the Merger and the other transactions contemplated by the Merger Agreement as promptly as practicable, including obtaining third-party approvals necessary to consummate the Merger, and Alcon’s obligation to take all actions 
 necessary, proper or advisable to eliminate any impediment under antitrust or foreign investment laws and obtain certain required                                                                                                             |

-49-

| regulatory approvals, subject to certain limitations set forth in the Merger Agreement (as discussed in the section of this proxy statement titled “The Merger Agreement—Efforts to 
 Close the Merger”);                                                                                                                                                                 |

| • |     | the Alcon Termination Fee of $72,375,000 (representing approximately 5% of STAAR’s implied equity value)                                                                                                                              
 payable to STAAR if the Merger Agreement is terminated in certain circumstances relating to a failure to timely receive certain required regulatory approvals (as discussed in the section of this proxy statement titled “The Merger 
 Agreement—Efforts to Close the Merger”);                                                                                                                                                                                              |

| • |     | STAAR’s ability to seek specific performance of Alcon’s and Merger Sub’s obligations to cause                      
 the Merger to occur and to prevent breaches of the Merger Agreement, subject to the terms of the Merger Agreement; |

| • |     | STAAR management’s view that STAAR has sufficient operating flexibility under the terms of the Merger 
 Agreement to conduct its business prior to the consummation of the Merger; and                        |

| • |     | the fact that the definition of “Material Adverse Effect” excludes certain